In a retrospective study of 71 BRCA1/2 associated pancreatic cancer, unresectable pancreatic cancer patients treated with platinum agents had significantly longer OS than those treated with non-platinum agents (22 vs. 9 months; p = 0.039) [131]. This evidence concerns the gene BRCA1 and familial pancreatic carcinoma.